Jan 20 (Reuters) - AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq ...

The approval is supported by data from the DESTINY-Gastric04 Phase III trial.

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

Key Insights Using the 2 Stage Free Cash Flow to Equity, AstraZeneca fair value estimate is UK£250 AstraZeneca's ...

AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory review after strong trial results.

The company says the proposal will create space for hundreds of its staff to work at the campus.

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. AstraZeneca PLC is placed fourth on our list among the ...

By Maggie Fick SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on ...

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

CNW/ - AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.